Edgewise Therapeutics (EWTX) Preferred Stock Liabilities (2020)

Edgewise Therapeutics has reported Preferred Stock Liabilities for 1 years, with the latest figure at $160.2 million in Q4 2020.

• Quarterly Preferred Stock Liabilities changed N/A year-over-year to $160.2 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $160.2 million (changed N/A YoY) and the FY2020 annual result came in at $160.2 million, changed N/A from the prior year.
• Preferred Stock Liabilities held at $160.2 million in Q4 2020 per EWTX's latest filing.
• Over five years, Preferred Stock Liabilities peaked at $160.2 million in Q4 2020 and troughed at $160.2 million in Q4 2020.